$ZLAB News
Last published 6d ago
- 6d agoZLABZai Lab Third Quarter 2026 Financial Results - ZAI LAB LTDEarnings Call TranscriptsLadies and gentlemen, thank you for standing by and welcome to Xylep's Asset Quota 2026 Financial Results Conference call. At this time, all participants are in the listen-only mode. Later, we will conduct a question and
- 6d agoZLABZai Lab Ltd - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoZLABZai Lab 2026 ESMO Investor Call - ZAI LAB LTDEarnings Call TranscriptsHello, everyone, and thank you for joining us for the presentation of the results from our Phase I study evaluating SOZI, our DLL-3-targeted ADC in combination with atezolizumab with or without carboclatin in small cell
- 2w agoZLABZai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung CancerBusiness WireAt the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L
- 2w agoZLABZai Lab Announces $250 Million Private PlacementBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares
- 3w agoZLABZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026Business Wire- Company to host conference call and webcast on November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its third quarter 2026 financial
- 4w agoZLABZai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic DiseasesBusiness Wire- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting - Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and
- 1mo agoZLABZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Business WirePoster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin Data adds to body of evidence supporting zoci as a potential
- 1mo agoZLABOpenAI and Anthropic are making 10 times more revenue than all Chinese AI models combined, research group Rhodium saysCNBCRhodium Group's latest analysis of Chinese and U.S. AI companies also found that low revenue did not necessarily correspond with lower valuation.
- 1mo ago2513-HK100-HKZLABZ.ai shares tumble over 10% after $5 billion fundraising, its second major raise in two monthsCNBCZ.ai shares tumbled after the Chinese AI company announced its second major fundraising in two months.
- 2mo agoZLABARGXZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisBusiness WireStudy met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study;
- 3mo agoZLABZai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate UpdatesBusiness WireThe Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 Global Phase 1 data for
- 3mo agoZLABU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)Business Wire- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need - U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary
- 3mo agoZLABZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026Business Wire- Company to host conference call and webcast on August 6, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its second quarter 2026 financial
- 3mo ago2513-HK100-HKZLABBABA+1Chinese startup Moonshot AI unveils Kimi model it says rivals OpenAI, AnthropicCNBCIt's the latest AI model from China to close the performance gap with leading U.S. AI labs.
- 4mo agoZLABZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine CarcinomasBusiness Wire- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies in relapsed or
- 5mo agoZLABZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerBusiness Wire- TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously treated recurrent or metastatic cervical cancer in China - TIVDAK demonstrated a statistically significant overall survival
- 5mo agoZLABZai Lab Announces Changes to Senior Leadership TeamBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision
- 6mo agoZLABZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)Business Wire- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has
- 6mo agoZLABZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesBusiness Wire– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for
- 6mo agoZLABZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026Business Wire- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its first quarter 2026 financial results and
- 6mo agoZLABZai Lab 2026 AACR Investor CallZAI LAB LTDEarnings Call TranscriptsHello, ladies and gentlemen. Thank you for standing by and welcome to Xylep's 2026 AACR Investor Call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session and inst
- 6mo agoZLABZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesBusiness Wire-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of
- 6mo agoZLABZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasBusiness WireZoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose,
- 7mo agoZLABBoehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasGlobeNewswireBoehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will
- 7mo agoAMGNZLABZai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager TherapyBusiness Wire- Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai
- 7mo agoZLABZai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)Business Wire- Zoci data show intracranial response in small-cell lung cancer (SCLC) with brain metastases, as well as activity in other neuroendocrine carcinomas - ZL-6201 will be highlighted in a poster presentation showcasing its
- 8mo agoZLABZai Lab Full-Year 2025 Financial ResultsZAI LAB LTDEarnings Call TranscriptsThank you, Operator. Hello and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Xilab's founder, CEO, and chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr.
- 8mo agoZLABZai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesBusiness Wire– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global
- 9mo agoZLABZai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026Business Wire- Company to host conference call and webcast on February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its fourth quarter and full year 2025
- 9mo agoONCYRLAYMAIAZLAB+1$207B Market Shift: The Race for Fast Track Approval in OncologyPR NewswireUSANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued...
- 10mo agoZLABZai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid TumorsBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for
- 10mo agoZLABZai Lab to Present at 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, at
- 10mo agoZLABZai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for SchizophreniaBusiness WireCOBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included in China's national-level schizophrenia
- 11mo agoZLABZai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic DermatitisBusiness Wire- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab's growing global pipeline - ZL-1503 originated from Zai Lab's in-house
- 11mo agoZLABZai Lab Announces Updates to China's National Reimbursement Drug ListBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China's National Healthcare
- 1y agoZLABZai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness Wire– Zocilurtatug pelitecan (zoci, DLL3 ADC) (formerly ZL-1310) data presented at Triple Meeting in October continues to demonstrate first- and best-in-class potential, supporting the recent initiation of the global
- 1y agoZLABZai Lab Announces Participation in Investor Conferences in November and December 2025Business WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in November and December 2025: Jefferies Global
- 1y agoZLABZai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational StudyBusiness Wire- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with baseline brain metastases (n=32), including an 80% ORR for patients
- 1y agoONCZLABCRVSDNA+2The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive PartnersPR NewswireThe Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of...
- 1y agoZLABZai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025Business Wire- Company to host conference call and webcast on November 6, 2025, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its third quarter 2025 financial
- 1y agoZLABZai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC ConferenceBusiness Wire- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a promising next-generation, first- and best-in-class, Delta-like ligand (DLL3)-targeted
- 1y agoZLABZai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoONCYNEOGHCLRB+1Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market ExpandsPR NewswireCancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain...
- 1y agoZLABZai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong KongBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic
- 1y agoZLABZai Lab Announces Participation in Investor Conferences in September 2025Business WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in September 2025: Cantor Global Healthcare
- 1y agoZLABZai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic CancerBusiness WireZai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for
- 1y agoZLABZai Lab Establishes Oncology Scientific Advisory BoardBusiness Wire- Newly formed Advisory Board comprises world-class leaders in oncology to support advancement of Zai Lab's robust oncology products and pipeline Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the creation
- 1y agoZLABZai Lab Limited (ZLAB) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoZLABZai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness WireTotal revenues grew 9% y-o-y to $110.0 million for the second quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million VYVGART reached record patient utilization in the second